Form 8-K - Current report:
SEC Accession No. 0001641172-25-011962
Filing Date
2025-05-22
Accepted
2025-05-22 06:05:34
Documents
15
Period of Report
2025-05-19
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K form8-k.htm   iXBRL 8-K 44596
2 EX-10.1 ex10-1.htm EX-10.1 220463
3 EX-99.1 ex99-1.htm EX-99.1 30403
4 GRAPHIC ex99-1_001.jpg GRAPHIC 25457
  Complete submission text file 0001641172-25-011962.txt   551606

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE evfm-20250519.xsd EX-101.SCH 3009
6 XBRL LABEL FILE evfm-20250519_lab.xml EX-101.LAB 34240
7 XBRL PRESENTATION FILE evfm-20250519_pre.xml EX-101.PRE 24161
17 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3652
Mailing Address 12400 HIGH BLUFF DRIVE SUITE 600 SAN DIEGO CA 92130
Business Address 12400 HIGH BLUFF DRIVE SUITE 600 SAN DIEGO CA 92130 (858) 550-1900
Evofem Biosciences, Inc. (Filer) CIK: 0001618835 (see all company filings)

EIN.: 208527075 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36754 | Film No.: 25974666
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)